Microarray urls:
165.123.33.33
nhgri.nih.gov
syntom.cit.cornell.edu
industry.ebi.ac.uk
-------------
Are any of the following questions good ones?
Biotech companies need to do high-throughput screening
of optimized lead compounds to see how they effect the
target genes. They need to do comparisons of diseased
and healthy tissue, and they also want to watch the
interactions between proteins.
These chips need to be sensitive to very small tissue
samples right? Ideally you would want to watch things
at the individual cellular level--no sense listening
to the whole symphony if only the French Horn is out
of tune--intracellular signaling might be the jargon.
Okay, how 'bout some help here. Ah, just remembered,
there was an article at Biospace.com, "The Matrix"
that is one to read again.
Shoot, I cant remember too much about why I thought
Gene Logic's "Flow-Thru" chip was so great--surely
Affy has chips just as good or better? I remember they
were reusable, and very sensitive...but what does
sensitive mean? One transcript? What sort of sensitivity
does affy claim?
Another question--these genomic, pharmacogenetic,
bioinformatic, proteomics etc etc oriented companies...
they are all pounding out software that needs to handle
many terabytes of data right? That is what you keep
reading--how does gene expression analysis generate
so much data--these chips are built to target hundreds
of genes, then you sift through hundreds of thousands
(millions?) of lead compounds. How does that generate
terabytes of data? Proteomics I understand, lotsa
protiens. But in genomics, not a lot of genes really. |
